THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
98.71%
Total 13F principal
$101,891,500
Principal change
+$12,624,550
Total reported market value
$100,823,653
Number of holders
18
Value change
+$10,989,918
Number of buys
4
Number of sells
4

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q2 2022

As of 30 Jun 2022, THERAVANCE INC - CORPORATE OBLIG was held by 18 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $101,891,500 in principal (par value) of the bond. The largest 10 bondholders included WOLVERINE ASSET MANAGEMENT LLC, Walleye Capital LLC, LAZARD ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., BNP PARIBAS ARBITRAGE, SA, DEUTSCHE BANK AG\, CSS LLC/IL, TORONTO DOMINION BANK, SSI INVESTMENT MANAGEMENT LLC, and WELLS FARGO & COMPANY/MN. This page lists 18 institutional bondholders reporting positions for the Q2 2022 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.